Yishen Daluo Yin granules for relapsing-remitting multiple sclerosis
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests a traditional Chinese medicine granule called Yishen Daluo Yin for people with relapsing-remitting multiple sclerosis (RRMS). The goal is to see if it reduces relapses and is safe. You may qualify if you have had MS flare-ups recently but are currently stable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 55 years old.
- You have relapsing-remitting multiple sclerosis (not the progressive type).
- You have had at least 1 MS relapse in the past 2 years.
- You have no active relapses for at least 30 days before starting.
- Your disability level is low to moderate (able to walk without help).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a Chinese herbal formula (Yishen Daluo Yin) to standard multiple sclerosis medications helps manage the disease better. It may be an option if you have relapsing MS and are stable on a first-line drug.
This trial tests an experimental drug called AZD0120 in adults with multiple sclerosis. It is designed for people with relapsing or progressive forms of MS who have not responded well to other treatments or have active disease.
This trial tests whether treating relapsing multiple sclerosis (RRMS) aggressively and early with a specific medication can slow disease progression. You may qualify if you were recently diagnosed, have had recent disease activity, and are willing to take a strong immunosuppressive drug with regular MRI monitoring.
This trial tests a new medicine called BCD-281 for people with relapsing-remitting multiple sclerosis (RRMS). It aims to see if the drug can reduce relapses and improve disease control.
This trial tests a new cell therapy called YTB323 for people with relapsing multiple sclerosis (RMS) that is still active despite strong treatments. The treatment aims to reset the immune system to stop attacks on nerves.
This study tests an experimental drug given as an injection under the skin for people with relapsing multiple sclerosis (MS). The goal is to see if it can reduce relapses and slow down the disease.
Hear when a new Relapse Remitting Multiple Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.